Novartis Reaches Licensing Deal with PTC Therapeutics for Huntington’s Disease Treatment
- December 06, 2024
Novartis Pharmaceuticals Corp. has reached a licensing deal with PTC Therapeutics for the biotech’s Huntington's disease program in a deal valued at up to $2.9 billion.
ARTICLE TAGS
You must be logged in to access this content.